United States-based Melior Pharmaceuticals' insulin sensitiser, tolimidone (MLR-1023), has succeeded in a phase 2b trial in Type two diabetes mellitus (T2DM), it was reported yesterday.
According to the company, the product significantly decreased HbA1c in comparison to placebo in the mid-stage trial as per the analysis of all patients who were subjected to the full course of treatment. The investigational drug is a Lyn kinase activator that plays the roles of a dual non-PPAR insulin sensitiser and modulator of lipid metabolism.
The company stated that the phase 2b study confirmed the product's ability to decrease fasting glucose and improve glucose tolerance over a 12-week treatment regimen. Furthermore, the insulin sensitiser had indicated a safety profile in the phase 2b study that was on par with that observed in previous clinical trials. However, the company revealed that there were errors in the clinical trial supplies, which indicate that the treatment effect could have been attenuated due to mix-ups in dosing. The firm stated that the full extent of the mistakes and the source of their origin are being probed. Before the completion of the phase 2b study in T2DM, Melior decided to extend the clinical development of tolimidone into nonalcoholic steatohepatitis.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults